Join the Global Community of Liver Experts in Paris!

The First Annual Paris International Liver Meeting, January 19-21, 2026.

Register NowDownload Program

Editorial

It is our great pleasure to announce the First Annual Paris International Liver Meeting to be held in Paris (Maison de la Chimie) from January 19-21, 2026.

This meeting will bring together leading experts, clinicians, researchers, biopharmaceutical industry and healthcare professionals from around the world to share the latest clinically relevant advances in the management and treatment of chronic liver diseases.

Over three days, the program will explore and provide up-to-date short reviews by the best experts on the different aspects of clinical hepatology, including, viral hepatitis, cholestatic liver diseases, complications of cirrhosis, metabolic and alcohol-related liver diseases, and liver cancer.

Throughout the meeting, attendees will have the opportunity to interact with thought leaders and the industry with the aim of improving the management of patients.

We look forward to seeing you in Paris!

Laurent Castera, MD PhD
Zobair M. Younossi, MD
Co-Chairs, Paris International Liver Meeting   

Accreditation 2026

The PARIS INTERNATIONAL LIVER MEETING, PARIS, France 19/01/2026 - 21/01/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications. 

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Organized by

Laurent CASTERA, MD, PhD
France

Professor of Hepatology, Head of the NASH/MASH ProgramDepartment of Hepatology, Hôpital Beaujon, AP-HPINSERM UMR 1149, Centre de Recherche sur l’Inflammation Paris Montmartre, Université Paris-Cité, Clichy, France

Zobair M YOUNOSSI, MD, MPH
USA

Chairman of the Global NASH/MASH Council, Washington DC, USAProfessor and Chairman of Beatty Liver and Obesity Research, Inova Health System, Falls Church, VA, USA

With the scientific support of